AtaGenix Laboratories
AtaGenix Laboratories
AtaGenix's Xten™ Mab Single B Cell rabbit monoclonal antibody platform bypasses hybridoma fusion entirely — isolating antigen-specific B cells by FACS, amplifying VH/VL genes by single-cell PCR, and expressing full-length rabbit IgG via our XtenCHO™ mammalian system. The result: high-affinity rabbit mAbs with complete sequence data, delivered in 16–20 weeks with at least 3 optimized candidates.
10–100x
Affinity vs. Rodent mAbs
16–20
Weeks to Delivery
≥3
Optimized Candidates
Full
Sequence Data Included
Rabbit mAbs outperform rodent antibodies on nearly every dimension: the rabbit immune system generates 10–100-fold higher affinity through more aggressive somatic hypermutation, recognizes a broader range of epitopes including PTMs and small molecules, and produces structurally stable IgG with natural heavy–light chain pairing. Because the technology works at the single-cell level, there is no clone loss from hybridoma instability.
| Feature | Rabbit Single B Cell | Mouse Hybridoma | Phage Display |
| Affinity | 10–100x higher than mouse | Baseline | Variable (may need maturation) |
| Epitope Diversity | Excellent (PTMs, small molecules) | Good | Library-dependent |
| Clone Stability | No hybridoma = no clone loss | Risk of clone drift/loss | Sequence-based, stable |
| Sequence Obtained | Directly from single cell | Requires re-cloning | Directly from panning |
| Humanization Path | Easier (simpler IgG framework) | Standard CDR grafting | Human library = no humanization |
No Hybridoma = No Clone Loss
Antibody genes are amplified directly from individual B cells by PCR. No fusion, no myeloma partner, no risk of chromosome loss or clone drift over passages. Every sequence you get is permanent.
FACS-Enriched, Not Random
Antigen-specific B cells are enriched by flow cytometry before single-cell sorting. This focuses the effort on high-affinity producers from the start, rather than screening thousands of random hybridoma clones.
XtenCHO™ Recombinant Expression
Selected antibody sequences are expressed as full-length rabbit IgG in our XtenCHO™ mammalian system — ensuring correct folding, glycosylation, and functional activity. 100 µg per candidate delivered.
AtaGenix's Xten™ Mab platform isolates antigen-specific rabbit B cells by FACS sorting from immunized spleens (serum titer >128K), amplifies paired VH/VL genes from individual B cells by single-cell RT-PCR, analyzes sequence diversity, and expresses the top candidates as full-length recombinant rabbit IgG in the XtenCHO™ mammalian system. Deliverables include at least 3 optimized antibody sequences (pUC plasmid), 100 µg purified protein per candidate, ELISA/WB/FC functional validation data, and a complete technical report. Typical timeline: 16–20 weeks from antigen to delivered antibodies.
A 5-stage pipeline from antigen preparation through recombinant antibody delivery. FACS-based B cell enrichment is the critical differentiator versus hybridoma. Total timeline: 16–20 weeks.
01
Antigen & Immunization
Antigen preparation
Rabbit immunization
Serum titer confirmation (>128K)
02
B Cell Isolation
Spleen / PBMC isolation
Antigen-specific FACS sorting
Single B cell plating
03
VH/VL Amplification
Single-cell RT-PCR
VH + VL gene recovery
Sequence analysis & diversity
04
Recombinant Expression
XtenCHO™ mammalian system
Full-length rabbit IgG
Purification (Protein A)
05
Validation & Delivery
ELISA, WB, FC validation
100 µg / candidate
Sequences + pUC plasmid + report
Service Scope
| ✓ Antigen preparation (optional, or client-provided) | ✓ Rabbit immunization & titer monitoring |
| ✓ FACS-based antigen-specific B cell sorting | ✓ Single-cell RT-PCR (paired VH/VL) |
| ✓ Sequence analysis & diversity assessment | ✓ XtenCHO™ recombinant expression (full-length IgG) |
| ✓ Protein A purification (100 µg / candidate) | ✓ Functional validation: ELISA, WB, flow cytometry |
| ✓ Deliverables: ≥3 antibody sequences + pUC plasmid | ✓ Complete technical report with QC data |
Case Highlight — Anti-human CD86 rabbit mAb: rabbits with serum titer >128K selected, PBMCs isolated, FACS-sorted for CD86-specific B cells. Top candidates expressed via XtenCHO™, ELISA-validated with EC50 ranging from 6.9 to 145 ng/mL across 4 lead antibodies.
Need a different discovery approach? Phage Display for fully human antibodies without immunization. Immune Library Construction for custom species-specific libraries. Mouse hybridoma for traditional mAb when rabbit is not required.
Why rabbit mAbs instead of mouse?
The rabbit immune system undergoes more aggressive somatic hypermutation and gene conversion, producing antibodies with 10–100-fold higher affinity than rodent equivalents. Rabbits also recognize a broader epitope repertoire — including post-translational modifications (phosphorylation, methylation, acetylation), small molecules, and conformational epitopes that mice often miss. Their IgG has a simpler, more stable framework that is easier to humanize for therapeutic development.
Why Single B Cell instead of rabbit hybridoma?
Rabbit myeloma cell lines are protected by patents, making traditional hybridoma fusion commercially restricted. Single B cell technology bypasses this entirely by working at the genetic level — PCR-amplifying antibody genes directly from sorted B cells. This also eliminates clone loss from hybridoma instability and delivers complete VH/VL sequences immediately, without the need for re-cloning or sequencing after the fact.
What do I receive at the end of the project?
At least 3 optimized rabbit monoclonal antibody candidates, each delivered as: complete VH/VL sequence data, pUC plasmid containing the antibody gene, 100 µg purified recombinant protein (full-length rabbit IgG expressed in XtenCHO™), and functional validation data (ELISA, WB, and/or FC as applicable). A comprehensive technical report covers immunization, sorting, sequencing, expression, and QC results.
How long does the project take?
16–20 weeks from project kickoff to delivered antibodies. This includes antigen preparation, rabbit immunization with titer monitoring, spleen/PBMC collection, FACS sorting, single-cell PCR, sequence analysis, recombinant expression, purification, and functional validation. Timeline can be shortened if the client provides antigen and/or immunized animals.
Affinity and hit rate are target-dependent. Rabbit single B cell technology is particularly recommended for PTM-specific antibodies, small molecule targets, and projects requiring easy downstream humanization. Cross-link URLs should be confirmed with actual page IDs before publishing. Quote-based pricing.
AtaGenix's recombinant antibody expression pipeline delivers assay-grade antibody from sequence to validated reagent. This case demonstrates the full QC workflow: SDS-PAGE (reducing + non-reducing) confirming correct HC/LC assembly and purity, SEC-HPLC verifying monomer content, endotoxin testing by LAL, and functional validation confirming antigen-specific binding. Every batch ships with dual verification — purity and function — ensuring the antibody works in the client's downstream application on the first attempt.
Using rabbit single B-cell antibody technology, an Anti-human CD86 rabbit monoclonal antibody was developed. Rabbits with serum titers greater than 128K were selected, and PBMCs were isolated for flow sorting to obtain human CD86 antigen-specific B-cell plates.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
